Jaguar Health/$JAGX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Jaguar Health
Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders. It has two reportable segments namely human health and animal health. The company generates the majority of its revenue from the Human Health segment.
Ticker
$JAGX
Sector
Primary listing
Employees
49
Headquarters
Website
Jaguar Health Metrics
BasicAdvanced
$6.9M
-
-$26.56
0.60
-
Price and volume
Market cap
$6.9M
Beta
0.6
52-week high
$15.48
52-week low
$1.57
Average daily volume
180K
Financial strength
Current ratio
0.955
Quick ratio
0.121
Long term debt to equity
170.087
Total debt to equity
443.75
Profitability
EBITDA (TTM)
-30.938
Gross margin (TTM)
81.88%
Net profit margin (TTM)
-344.16%
Operating margin (TTM)
-278.13%
Revenue per employee (TTM)
$240,000
Management effectiveness
Return on assets (TTM)
-37.42%
Return on equity (TTM)
-319.25%
Valuation
Price to revenue (TTM)
0.276
Price to book
0.59
Price to tangible book (TTM)
-0.27
Price to free cash flow (TTM)
-0.117
Free cash flow yield (TTM)
-855.80%
Free cash flow per share (TTM)
-18.228
Growth
Revenue change (TTM)
15.95%
Earnings per share change (TTM)
-9.83%
3-year revenue growth (CAGR)
12.67%
Jaguar Health News
AllArticlesVideos
Jaguar Health Completes Meeting with FDA for Advice on Development Pathways to Advance Ongoing Crofelemer Trial for Potential Approval for Treatment of Pediatric Indication Microvillus Inclusion Disease (MVID)
Accesswire1 week ago
FDA-Authorized Expanded Access Programs Utilizing Jaguar Health's Novel Crofelemer Powder for Oral Solution to Treat Two Pediatric Intestinal Failure Patients with Microvillus Inclusion Disease
Accesswire2 weeks ago
Jaguar Health Receives Notice of $250,000 FDA Grant to Fund Confirmatory Trial to Support FDA Approval of Canalevia for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs
Accesswire3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Jaguar Health stock?
Jaguar Health (JAGX) has a market cap of $6.9M as of October 14, 2025.
What is the P/E ratio for Jaguar Health stock?
The price to earnings (P/E) ratio for Jaguar Health (JAGX) stock is 0 as of October 14, 2025.
Does Jaguar Health stock pay dividends?
No, Jaguar Health (JAGX) stock does not pay dividends to its shareholders as of October 14, 2025.
When is the next Jaguar Health dividend payment date?
Jaguar Health (JAGX) stock does not pay dividends to its shareholders.
What is the beta indicator for Jaguar Health?
Jaguar Health (JAGX) has a beta rating of 0.6. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.